Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 13/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937840 | 1.00 | RBP4 (0.50) | RBP4CNR2GAAKDM4EALDH1A1 | |
| SCHEMBL1410314 | 0.84 | NOTUM (0.50) | CNR2KMT2ANOTUM | |
| SCHEMBL19937836 | 0.82 | RBP4 (0.48) | RBP4GAAMEN1USP2KMT2A | |
| SCHEMBL19937835 | 0.81 | RBP4 (0.47) | RBP4GAAMEN1USP2KMT2A | |
| SCHEMBL19937833 | 0.81 | RBP4 (0.47) | RBP4GAAMEN1USP2KMT2A | |
| SCHEMBL16559748 | 0.80 | ALDH1A1 (0.40) | CNR2GAAKDM4EALDH1A1MEN1 | |
| SCHEMBL19937827 | 0.80 | RBP4 (0.51) | RBP4ALDH1A1 | |
| SCHEMBL19937838 | 0.80 | RBP4 (0.51) | RBP4ALDH1A1 | |
| SCHEMBL19937826 | 0.80 | RBP4 (0.51) | RBP4ALDH1A1 | |
| SCHEMBL19937832 | 0.78 | RBP4 (0.44) | RBP4GAAMEN1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | RBP4 4859/4885CNR2 4165/4885GAA 1670/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | RBP4 4859/4885CNR2 4165/4885GAA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.